Rexahn Pharmaceuticals, Inc. (NYSE:RNN)‘s stock had its “outperform” rating reiterated by analysts at FBR & Co in a report issued on Wednesday. They currently have a $3.00 price target on the stock.

Separately, Zacks Investment Research lowered shares of Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 11th.

Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.2132 on Wednesday. The company has a 50-day moving average of $0.24 and a 200-day moving average of $0.27. Rexahn Pharmaceuticals has a one year low of $0.20 and a one year high of $0.52. The company’s market capitalization is $45.48 million.

Rexahn Pharmaceuticals (NYSE:RNN) last posted its earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. On average, analysts anticipate that Rexahn Pharmaceuticals will post ($0.07) earnings per share for the current year.

A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned 2.30% of Rexahn Pharmaceuticals worth $1,232,000 as of its most recent SEC filing.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

5 Day Chart for NYSE:RNN

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.